摘要
目的探讨低剂量利伐沙班应用于急性肺栓塞患者的近期疗效及安全性。方法本研究为病例对照研究。选取中山市人民医院2019年1月至2021年4月收治的112例急性肺栓塞患者, 随机分为试验组和对照组。对照组给予利伐沙班15 mg, 2次/d, 3周后改为20 mg, 1次/d;试验组给予利伐沙班10 mg, 2次/d, 3周后改为15 mg, 1次/d;疗程3个月。比较2组患者的近期临床疗效、出血发生率、住院时间及医疗费用。结果 2组患者近期疗效相当(P>0.05);试验组出血发生率明显低于对照组(χ^(2)=4.15, P<0.05), 试验组住院时间、门诊及住院费用均低于对照组(t值分别为2.53、3.88、2.46, P值均<0.05)。结论低剂量与常规剂量利伐沙班对急性肺栓塞患者近期疗效相当, 应用低剂量利伐沙班出血发生率更低, 住院时间更短, 门诊及住院费用更低, 值得在临床推广使用。
Objective To investigate the short-term efficacy and safety of low dose rivaroxaban for patients with acute pulmonary embolism.Methods A total of 112 patients with acute pulmonary embolism were randomly divided into experimental group and control group.The control group was given rivaroxaban 15 mg twice a day,changed to 20 mg once a day after three weeks;the experimental group was given rivaroxaban 10 mg twice a day,and changed to 15 mg once a day after three weeks.The course of treatment was three months.The short-term efficacy,incidence of bleeding,length of stay and medical expenses of the two groups were compared.Results The short-term efficacy of the two groups was similar(P>0.05);the incidence of bleeding in the experimental group was significantly lower than that in the control group(χ^(2)=4.15,P<0.05).The average length of stay,outpatient and hospitalization expenses in the experimental group were significantly lower than those in the control group(t=2.53,3.88,2.46,all P<0.05).Conclusions Compared with conventional dose,low dose of rivaroxaban for treating patients with acute pulmonary embolism has the same effect,lower incidence of bleeding,shorter hospital stay,and lower outpatient and hospitalization expenses,which implies low dose is worthy of clinical application.
作者
张安兵
袁小玲
夏秀琼
吕燕华
张丹丹
梁剑平
Zhang Anbing;Yuan Xiaoling;Xia Xiuqiong;Lyu Yanhua;Zhang Dandan;Liang Jianping(Department of Respiratory and Critical Care Medicine,Zhongshan People′s Hospital,Zhongshan 528400,China)
出处
《国际呼吸杂志》
2022年第4期275-278,共4页
International Journal of Respiration
基金
广东省医学科学技术研究基金(C2019032)
中山市医学科研项目(2021J096)。
关键词
急性肺栓塞
利伐沙班
低剂量
疗效
安全性
Acute pulmonary thromboembolism
Rivaroxaban
Low dose
Curative effect
Safety
